
    
      All eligible participants will be randomized to receive a single injection of either one of
      the high-dose quadrivalent influenza vaccine formulations or one of the high-dose trivalent
      influenza vaccines at Day 0. They will provide blood samples for hemagglutination inhibition
      (HAI) testing. Safety information as solicited, unsolicited reactions, serious adverse
      events, including adverse events of special interest will be collected in the trial.
    
  